Treatment Adherence & Relapse Prevention in Schizophrenia

John Donoghue
Liverpool
Objectives

• To review the pivotal relationship between treatment adherence and outcome in schizophrenia

• To consider how better medicines management could aid adherence to treatment with antipsychotic medication

• To review data for relapse prevention with 2nd-generation antipsychotic medicines
Schizophrenia

- Most common form of psychotic disorder
- Lifetime prevalence 0.4% to 1.4%
- Over 80% of adults have persistent problems with social functioning
- Mortality approx 50% above that of the general population
Outcomes of public concern in schizophrenia

Kooyman I, Dean K, Harvey S & Walsh E
Outcomes of public concern in schizophrenia
Br J Psychiatry 2007;191:29-36

Copyright © John Donoghue 2012
Revolving door = vicious cycle

Delay in treating first episode

Treatment response but subsequent poor adherence to treatment

Progression to chronic illness and/or treatment resistance

Relapse & need to re-establish treatment
2-year Outcomes in UK

% of patients (N=1,015)

- Hospital admission
- Self-harm
- Suicide attempt
- Civil detention in past 12 months
- Care Programme Approach

Hunter R, Cameron R, Norrie J.
Using patient-reported outcomes in schizophrenia: The Scottish Schizophrenia Outcomes Study
Psychiatric Services 2009;60:240-245
WHO: Conclusions about poor treatment adherence

- A problem of striking magnitude
- Poor health outcomes and increased costs
- Influenced by multiple factors
- Patient-tailored interventions are required

World Health Organization
Adherence to long-term therapies: Evidence for action
Geneva, WHO 2003
http://www.who.int/chp/knowledge/publications/adherence_introduction.pdf
Clinicians often underestimate poor adherence in their patients

- Electronic medication event monitoring system (MEMS)
  - Adherence ratings collected from:
    - Clinicians
    - Patients
    - MEMS
  - 6 consecutive monthly visits
  - Non-adherence = <70% adherence for 2 or more months

Patient population:
Outpatients with schizophrenia (n=35) or schizoaffective disorder (n=26)

Byerly MJ, Thompson A, Carmody T et al.
Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia
Psychiatric Services 2007;58:844-7

Non-adherence rates (%)
When does poor adherence increase hospital admission?

- Retrospective review in USA
  - 4325 Medicaid outpatients with schizophrenia
- Adherence assessed using:
  - Gap in medication
  - Medication consistency
  - Medication possession ratio
- Study duration 1 year

Weiden PJ, Kozma C, Grogg A, Locklear J
Partial compliance and risk of rehospitalisation among California Medicaid patients with schizophrenia
Psychiatric Services 2004;55:886-91
When does poor adherence increase hospital admission?

Weiden PJ, Kozma C, Grogg A, Locklear J
Partial compliance and risk of rehospitalisation among California Medicaid patients with schizophrenia
Psychiatric Services 2004;55:886-91
Poor adherence in schizophrenia: a large and persistent problem

Systematic review of literature

• 39 studies from 1980 onwards
  – 10 retrospective, 15 cross-sectional, 14 prospective
• Mean duration of illness 10-24 years
• Range of adherence measures
• “Taking medication as prescribed at least 75% of the time”

49.5% of patients non-adherent

Adherence varies over time

- 4-year study in US Veterans Affairs system
- 34,128 patients with schizophrenia
- ‘Medication possession ratio’ (MPR) calculated

\[
MPR = \frac{\text{Number of days supply of antipsychotic obtained from pharmacy}}{\text{Number of days supply needed for continuous antipsychotic use}}
\]

- MPR <0.8 = poor adherence
- Cross-sectional prevalence of poor adherence was stable: 36%-37%

WHO: Conclusions about poor treatment adherence

- A problem of striking magnitude
- Poor health outcomes and increased costs
- Influenced by multiple factors
- Patient-tailored interventions are required

World Health Organization
Adherence to long-term therapies: Evidence for action
Geneva, WHO 2003
http://www.who.int/chp/knowledge/publications/adherence_introduction.pdf
Poor adherence in 1st episode schizophrenia leads to high rates of relapse

- 5-year follow-up study after initial recovery from first episode of schizophrenia or schizoaffective disorder
- 104 patients
- Discontinuation of antipsychotic medication increased risk of relapse almost 5-fold

Robinson D, Woerner MG, Alvir JMJ et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder
Arch Gen Psychiatry 1999;56:241-47
Preventing relapse in 1\textsuperscript{st} episode psychosis

- **Relapse Prevention Therapy (RPT)**
  - Shared written individual assessment of relapse risk
  - Phased systematic approach to relapse prevention – CBT interventions
  - Parallel individual and family relapse prevention CBT sessions
  - Supervision specifically focused on relapse prevention

- **Patients randomised to receive**
  - RPT N=41
  - Treatment as usual (TAU) N=40


![Graph showing relapse rates (%) at 7-month follow-up with p<0.05 vs TAU.]
Poor adherence in chronic schizophrenia leads to high rates of relapse

- Pooled analysis of 66 studies with 4365 patients with chronic schizophrenia
- Relapse rates over 10 month period

Number Needed to Harm for medication withdrawal*

**NNH = 3 (95% CI 2-3)**

* Calculated from the study results

** Data from 29 of the 66 studies where there were matched withdrawal and treatment maintenance groups

Poor adherence in schizophrenia leads to high rates of hospital admission

Estimates of annual admission rates %

Psychiatric admissions

<table>
<thead>
<tr>
<th></th>
<th>Adherent</th>
<th>Partial adherence</th>
<th>Non-adherent</th>
</tr>
</thead>
<tbody>
<tr>
<td>p-value</td>
<td>13.5</td>
<td>24.1*</td>
<td>34.9*</td>
</tr>
</tbody>
</table>

General admissions

<table>
<thead>
<tr>
<th></th>
<th>Adherent</th>
<th>Partial adherence</th>
<th>Non-adherent</th>
</tr>
</thead>
<tbody>
<tr>
<td>p-value</td>
<td>7</td>
<td>9.4*</td>
<td>13.3*</td>
</tr>
</tbody>
</table>

*p < 0.001 vs adherent group

Gilmer TP, Dolder CR, Lacro JP et al
Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia
Am J Psychiatry 2004;161:692-9
Poor adherence in schizophrenia is costly to the NHS

- UK Health economic study
- Data for 1 year (1994) from Office of Population Censuses and Surveys (OPCS)
- 658 patients taking antipsychotics identified
- Measures included frequency of use of:
  - In-patient care
  - Out-patient care
  - Community-based services
  - Day care / sheltered employment

- 1.5-fold increase in use of in-patient care
- 3-fold increase in costs of community-based services
- Increased in-patient cost of £2500 per patient
- Increased total cost of £5000 per patient

Knapp M, King D, Pugner K, Lapuerta P
Non-adherence to antipsychotic medication regimens: associations with resource use and costs
Br J Psychiatry 2004;184:509-16
WHO: Conclusions about poor treatment adherence

- A problem of striking magnitude
- Poor health outcomes and increased costs
- Influenced by multiple factors
- Patient-tailored interventions are required

World Health Organization
Adherence to long-term therapies: Evidence for action
Geneva, WHO 2003
http://www.who.int/chp/knowledge/publications/adherence_introduction.pdf
Adherence is influenced by multiple factors.

**Patient**
- Concerns about side effects
- Few perceived benefits
- Stigma
- Daily routine
- Concerns about dependence
- Lack of involvement

**Clinician**
- Poor therapeutic relationship
- Poor explanation / communication
- Inadequate follow-up

**General**
- Complexity of treatment
- Duration of treatment
- Lack of support

**Illness**
- Severity of illness
- Depression / psychosis
- Cognitive impairment

**Poor Adherence**

Mitchell AJ, Selmes T
Why don’t patients take their medicines? Reasons and solutions in psychiatry.
Advances in Psychiatric Treatment 2007;13:336-346
WHO: Conclusions about poor treatment adherence

• A problem of striking magnitude
• Poor health outcomes and increased costs
• Influenced by multiple factors
• Patient-tailored interventions are required
A strategy for preventing relapse

Medicines management

Individualise antipsychotic treatment

Engage patient by improving communication & information

Minimise complex treatment regimens

Ensure patient understands treatment regimen

Ensure easy access to repeat prescription

Adjust to daily routine
Individualising antipsychotic medication

- Offer oral antipsychotic medication.
- Provide information and discuss the benefits and side-effect profile of each drug with the service user.
- The choice of drug should be made by the service user and healthcare professional together, considering the relative potential of individual antipsychotic drugs to cause:
  - extrapyramidal side effects (including akathisia)
  - metabolic side effects (including weight gain)
  - other side effects (including unpleasant subjective experiences)
Once-daily dosing improves adherence

Systematic review of MEMS literature 1986 – 2007
(Range of chronic physical & neurological illnesses
No psychiatric illnesses were included in this analysis)

Once daily dosing:
• 13%-26% better adherence than bd dosing
• 22%-41% better adherence than tid dosing

Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC.
Effect of medication dosing frequency on adherence in chronic diseases
Am J Manag Care 2009;15:e22-33
Dosing frequency and adherence in schizophrenia and schizoaffective patients

Effect of increasing frequency of dose

- 1639 patients with ≥50% dose increase
- 1381 stayed on once-daily dosing before and after dose increase
  - No change in MPR
- 258 patients with increase in frequency of dosing
  - Significant reduction in MPR from 0.89 to 0.79 (p<0.001)

Effect of decreasing frequency of dose

- 1370 patients with dosing frequency reduced to once-daily
- Matched to 2740 controls
- OD dosing group
  - Significant improvement in MPR: 0.045
- Control group
  - Small reduction in MPR: -0.018 (p<0.001)

Pfeiffer P, Ganoczy D, Valenstein M
Dosing frequency and adherence to antipsychotic medications
Psychiatric Services 2008;59:1207-10
Relapse prevention with 2\textsuperscript{nd}-generation oral antipsychotic medicines (placebo-controlled studies)

- Aripiprazole
- Olanzapine
- Seroquel XL\(^\text{\ding{182}}\) (quetiapine prolonged release)

Data unavailable for oral risperidone

Please refer to individual SmPCs for licensed indications
Aripiprazole: relapse prevention

- 6 month randomised, double-blind, placebo controlled trial
- Patients clinically stable for 3 months prior to randomisation

** Number Needed to Treat* compared with placebo

\[ \text{NNT} = 4 \] (95% CI 3-8)

* Calculated from the study results

![Bar chart showing % of patients relapsing by endpoint](image)

- Placebo: 57% (N=149)
- Aripiprazole 15mg/day: 34% (N=148)

** p<0.001 vs placebo

NNT calculation made using University of British Columbia clinical significance calculator (http://spph.ubc.ca/sites/healthcare/files/calc/clinsig.html)

Please refer to SmPC for licensed indications

Olanzapine: relapse prevention

- 1 year randomised, double-blind, placebo controlled trial
- Patients stable on olanzapine 10-20mg/day for 2 months prior to randomisation

** Number Needed to Treat* compared with placebo

** NNT = 2 (95% CI 2-2)

* Calculated from the study results

NNT calculation made using University of British Columbia clinical significance calculator (http://spph.ubc.ca/sites/healthcare/files/calc/clinsig.html)

Please refer to SmPC for licensed indications

Beasley CM, Sutton VK, Hamilton SH, et al
A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.
J Clin Psychopharmacol 2003;23:582-94
Quetiapine XL: relapse prevention

- 1 year randomised, double-blind, placebo controlled trial

- Number Needed to Treat* compared with placebo

  **NNT = 2** (95% CI 2-2)

* Calculated from the study results

Estimated risk of relapse at 6 months (%)

- Placebo N=103
- Quetiapine XL N=94

** p<0.0001 vs placebo

** NNT calculation made using University of British Columbia clinical significance calculator (http://spph.ubc.ca/sites/healthcare/files/calc/clinsig.html)

Please refer to SmPC for licensed indications

Peuskens J, Trivedi J, Malyarov S et al
Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients
Psychiatry (Edgmont) 2007;4:34–50
Summary

• Poor adherence in schizophrenia is common and results in
  – High rates of relapse
  – High cost burden for the NHS

• Medicines management may offer a strategy to support adherence and prevent relapse
  – Individualising treatment
  – Minimising complex treatment regimens

• Second-generation antipsychotics are effective in preventing relapse in schizophrenia
Improving the use of medicines in severe mental illness

Medicines in Mental Health Ltd offers a range of services designed to obtain maximum benefit from medicines in the treatment of severe mental illness.

Thank you